![logo](/logos/TGTX.webp)
TG Therapeutics, Inc.
NASDAQ:TGTX
22.03 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | TG Therapeutics, Inc. |
Symbool | TGTX |
Munteenheid | USD |
Prijs | 22.03 |
Beurswaarde | 3,410,750,690 |
Dividendpercentage | 0% |
52-weken bereik | 6.46 - 25.7 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael S. Weiss Esq. |
Website | https://www.tgtherapeutics.com |
An error occurred while fetching data.
Over TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)